Beta DrugsNSE:BETA +3.01%88 Days Inventory is 188.24 as of Mar. 2026, which is 160% above its 10-year median of 72.39. GuruFocus rates NSE:BETA with a GF Score™ of 88/100 and a GF Value™ of ₹1,971.70 (Fairly Valued). The stock has 6 warning signs investors should review. Among 919 Drug Manufacturers companies, Beta Drugs ranks worse than 89.88% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Beta Drugs's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹745 Mil. Beta Drugs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹361 Mil.
Hence, Beta Drugs's Days Inventory for the
three
months ended in Mar. 2026 was 188.24.
The historical rank and industry rank for Beta Drugs's Days Inventory or its related term are showing as below:
NSE:BETA'
s Days Inventory Range Over the Past 10 Years
Min: 28.27 Med: 72.39 Max: 349.53
Current: 349.53
During the past 13 years, Beta Drugs's highest Days Inventory was 349.53. The lowest was 28.27. And the median was 72.39.
NSE:BETA's Days Inventory is ranked worse than 89.88% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs NSE:BETA: 349.53
Beta Drugs's Days Inventory
increased
from Dec. 2024 (117.48) to Mar. 2026 (188.24).
It might indicate that Beta Drugs's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Beta Drugs's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.48.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Beta Drugs's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.79.
Beta Drugs (NSE:BETA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Beta Drugs's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Beta Drugs's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Beta Drugs Days Inventory Related Terms
Beta Drugs Days Inventory Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Days Inventory distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Days Inventory of 188.24 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Beta Drugs and its competitors. This is 160% above median its historical median of 72.39. Over the past decade, Beta Drugs' Days Inventory has ranged from 28.27 to 349.53. According to the industry distribution chart, Beta Drugs ranks #826 out of 919 companies in the Drug Manufacturers industry, placing it in the top 89.9%.
Is Beta Drugs' Days Inventory too high?
Beta Drugs' current Days Inventory of 188.24 is 160% above median its 10-year median of 72.39. Over the past 10 years, this metric has ranged from a low of 28.27 to a high of 349.53. The Drug Manufacturers industry median Days Inventory is 164.48. Beta Drugs' value of 188.24 is 14.4% above this industry median. Based on the distribution chart, Beta Drugs ranks #826 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #826 out of 919 companies for Days Inventory. This places Beta Drugs in the lower half of its industry. The industry median Days Inventory is 164.48. Beta Drugs' value of 188.24 is 14.4% above this benchmark. Historically, Beta Drugs' own Days Inventory has ranged from 28.27 to 349.53 over the past decade. While the company's 10-year median is 72.39 vs. the industry median of 164.48, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Days Inventory of 188.24 is 14.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Days Inventory is 188.24, which is 160% above median its own 10-year median of 72.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,971.70, compared to a current price of ₹2,153.40 — trading 9.2% above its estimated fair value. The current Days Inventory is 188.24, which is 160% above median its 10-year median of 72.39 and 14.4% above the Drug Manufacturers industry median of 164.48. Beta Drugs' overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Days Inventory is 188.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,153.40 is trading 9.2% above its estimated GF Value™ of ₹1,971.70.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
Days Inventory: 188.24 (160% above median its 10-year median of 72.39)
GF Value™: ₹1,971.70 vs. price of ₹2,153.40 (9.2% above fair value)
Industry Position: 14.4% above the Drug Manufacturers median (#826 of 919)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
88GF Score
Get the complete analysis for NSE:BETA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
